Regina Berkovich
Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series
IntroductionAnti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and tolera…